Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Collaboration expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

CRISPR Therapeutics

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG and Vertex Pharmaceuticals are one step closer to gaining approval for their CRISPR/Cas9 gene editing therapy for Sickle Cell Disease and beta thalassemia. An FDA Advisory Committee raised a few concerns about the safety of the therapy yesterday, indicating a positive outlook for approval. The therapy has shown compelling efficacy in clinical trials, offering a potential cure for a debilitating disease that affects >100k.

CRISPR Therapeutics: Positive Exa-Cel AdCom Opens Door For Historic Approval

The FDA appears likely to approve Crispr's gene-editing approach to sickle cell disease, analysts said Wednesday as CRSP stock gapped higher.

Crispr Therapeutics Rallies On Bullish Views Of First-Ever Gene-Editing Drug

After being halted yesterday during the deliberations of a Food and Drug Administration (FDA) advisory committee, CRISPR Therapeutics (NASDAQ: CRSP ) stock is rallying 5% today in early trading. That's because the FDA panel appeared to view the company's treatment for sickle cell anemia, exa-cel, as safe.

CRSP Stock Alert: Can CRISPR Therapeutics Short Squeeze Higher?

Crispr Therapeutics AG's stock CRSP rallied 17% in premarket trade Wednesday, after a positive meeting of a . Food and Drug Administration advisory panel on the gene-editing drug exa-cel developed by Crispr and partner Vertex Pharmaceuticals VRTX as a treatment for sickle-cell disease.

Crispr Therapeutics' stock soars premarket after positive meeting of FDA panel on sickle-cell disease therapy

Vertex Pharmaceuticals

A panel of advisers to the U.S. health regulator said on Tuesday Vertex Pharmaceuticals and CRISPR Therapeutics could assess potential safety risks of their sickle cell disease gene therapy after approval.

FDA panel says Vertex/CRISPR to assess safety risks of gene therapy in follow-up study

-Exa-cel PDUFA target action date is December 8, 2023 for severe sickle cell disease (SCD)- ZUG, Switzerland and BOSTON, Oct. 31, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced the completion of the U.S. Food and Drug Administration's (FDA) Cellular, Tissue, and Gene Therapies Advisory Committee meeting for exagamglogene autotemcel (exa-cel) for the treatment of SCD in people ages 12 and older with recurrent vaso-occlusive crises (VOCs). Exa-cel is the first potential therapy to emerge from a strategic partnership between CRISPR Therapeutics and Vertex Pharmaceuticals.

CRISPR Therapeutics Announces Completion of FDA Advisory Committee Meeting for Exagamglogene Autotemcel (exa-cel) for Severe Sickle Cell Disease

The decision by an advisory committee may lead to Food and Drug Administration approval of the first treatment for humans that uses the CRISPR gene-editing system.

Panel Tells F.D.A. That CRISPR Sickle Cell Cure Is Safe Enough for Patients

Nearly all patients treated so far have been relieved of the blood-clogging crises of the disease.

FDA Advisors Consider Crispr Gene-Editing Treatment for Sickle Cell Anemia

Among the more prominent gene-editing stocks on the market, investors in this space pay particularly close attention to CRISPR Therapeutics (NASDAQ: CRSP ). That's due to the fact that CRISPR is among the leading players in the high-growth biotech industry developing gene-based medicines using CRISPR/Cas9 gene-editing technology.

CRSP Stock Halt: CRISPR Trading Halted Ahead of FDA Decision

CRISPR Therapeutics AG (CRSP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will CRISPR Therapeutics AG (CRSP) Report Negative Q3 Earnings? What You Should Know

ZUG, Switzerland and BOSTON, Oct. 31, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that NASDAQ has halted trading of the Company's common stock.

CRISPR Therapeutics Trading Halted Today; FDA Advisory Committee to Review Biologics License Application (BLA) for Exagamglogene Autotemcel (exa-cel) in Sickle Cell Disease (SCD)

Amgen

bluebird bio

Editas Medicine

Regeneron Pharmaceuticals

The Food and Drug Administration will hold an advisory committee meeting for the first CRISPR/Cas9 gene-edited product candidate this week. If approved, CRISPR Therapeutics and Vertex Pharmaceuticals' sickle cell disease therapy could generate blockbuster sales figures.

Gene Therapy Could Be On the Cusp of a Major Breakthrough, but Investors May Have to Remain Patient

Shares of genetic engineering specialist CRISPR Therapeutics (NASDAQ: CRSP ) moved up modestly on Friday as stakeholders await a final regulatory decision regarding a key therapeutic. Earlier, CRISPR generated significant scientific buzz for its exa-cel gene editing solution to address sickle cell disease.

CRSP Stock: FDA Considers Additional Review of CRISPR Therapeutics Gene Therapy

Etsy

CRISPR Therapeutics may soon launch its first approved product. The economic environment has weighed on Etsy, but recent trends show growth may be reaccelerating.

2 Fantastic Growth Stocks to Buy Hand Over Fist

Arcellx

Apogee Therapeutics Inc

Immunome

Nuvalent

Prime Medicine Inc

Vir Biotechnology

Biotechnology is the source of some of our strongest and growing revolutions. Gene technology allows us to cure incurable diseases and make miracles happen with living organisms.

7 Biotech Stocks to Get In Now Before Investors Catch On

The potential for CRISPR Therapeutics' pipeline is tremendous. However, an expected product approval may not offer the stock a huge lift.

CRISPR Therapeutics Stock: Bull vs. Bear

Intellia Therapeutics

Superstar investor Cathie Wood believes in buying innovators when they're down and holding for the long term. Her flagship fund is outperforming the S&P 500 this year.

Cathie Wood Is Buying These Top Growth Stocks -- and Both Could Make You Richer Over Time

Global X Genomics & Biotechnology ETF

Gene editing is revolutionizing how the world approaches medicine. In fact, by “simply” removing cells from the body, editing them, and reintroducing them, we could help treat sickle-cell anemia, cancers, blood disorders, blindness, cystic fibrosis, and even muscular dystrophy if all goes according to plan.

3 Gene Editing Stocks to Generate Super-Charged Gains

Superstar investor Wood looks for innovators whose products could be game changers down the road. She goes for companies that are undervalued today considering their long-term potential.

This Cathie Wood Stock Is Set to Soar 100%, Says Wall Street

Ginkgo Bioworks Holdings

There are a couple of stocks in the healthcare sector that could climb more than 100%, according to consensus estimates from Wall Street analysts. Analysts expecting CRISPR Therapeutics to launch its first drug next year think the stock could more than double from recent prices.

2 Growth Stocks That Could Double Your Money, According to Wall Street

Gene-editing stocks have gotten pummeled by the market's growing aversion to risk. Nonetheless, the field has made substantial progress of late.

2 Growth Stocks That Could Deliver Parabolic Returns in Under 5 Years

Here we discuss some reasons why investing in CRISPR Therapeutics (CRSP) stock now may turn out to be a more prudent move than ever.

Here's Why You May Invest in CRISPR Therapeutics (CRSP) Stock

CRISPR Therapeutics has upcoming catalysts and a strong cash position, making it a solid investment opportunity. The company's pipeline includes therapies for diabetes, immuno-oncology, and hemoglobinopathies, showcasing its diverse range of applications. Concerns include the lack of insider buying, regulatory approval challenges, market acceptance, and competition in the gene editing industry.

Crispr: Upcoming Catalysts, Plenty Of Cash And Strong Partnerships Make It A Buy

Cathie Wood is betting on CRISPR Therapeutics' ability to cure certain diseases through its gene editing techniques. The company is about to reach an important moment -- one that could lead to blockbuster revenue.

Cathie Wood Is Buying CRISPR Therapeutics Ahead of This Big Event. Should You?

Pfizer

AstraZeneca

Merck

Moderna

GlaxoSmithKline

Novartis

Sanofi

Scientists Katalin Karikó and Drew Weissman were awarded the Nobel prize this week for a discovery that went under the radar for many years, until it was found to hold the key to stabilising mRNA vaccines used in the fight against the Covid-19 pandemic.   The researchers own the patents to the nucleoside modification technology licensed out to drug companies such as BioNTech SE, where Karikó once worked, which developed an mRNA vaccine against Covid-19 with Pfizer Inc (NYSE:PFE), and Moderna Therapeutics Inc (NASDAQ:MRNA).

News for CRISPR Therapeutics Stock (CRSP)